Clinical application of circulating tumor cells in gastric cancer: advances and prospects

doi:10.16150/j.1671-2870.2023.04.002

Abstract

Abstract:

Malignant tumors seriously threat the health of the Chinese population. Circulating tumor cell (CTC), as molecular markers in liquid biopsy, have the advantage of being non-invasive and longitudinal monitoring of tumor progression and efficacy. In vitro CTC enrichment detection methods are divided into two types: based on molecular characteristics and based on physical characteristics. In recent years, a series of comprehensive CTC enrichment methods targeting different molecular characteristics have been developed, as well as the use of subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) for enrichment detection of gastric cancer CTC. Microfluidic technology can separate and enrich CTC on the same chip based on their molecular and physical characteristics simultaneously, helping to achieve more efficient and sensitive CTC enrichment detection. Compared with the in vitro CTC enrichment platform, the in vivo CTC enrichment platform has higher capture efficiency and detection sensitivity, but it is an invasive examination, and the impact on patients still needs further study. High CTC level is closely related to the disease control rate after gastric cancer chemotherapy and is an independent predictor of poor prognosis in gastric cancer patients. Among non-metastatic malignancies, increased CTC counts after surgery in patients with esophageal cancer and colorectal cancer are strongly associated with worse overall survival. Since CTC are highly heterogeneous, changes in CTC can be longitudinally monitored to provide a reference for the treatment of malignant tumors. Research on gastric cancer has shown that the positivity rate, size of circulating tumor microemboli (CTM) and gene expression level of CTC are closely related to the ability of invasion, metastasis, drug resistance and prognosis. The dynamic metastasis process and pattern of CTC play an important role in tumor metastasis. For the detection of CTC, it is necessary to establish unified standards and verification methods, and develop multi-omics research technology.

Key words: Circulating tumor cell, Gastric cancer, Therapeutical resistance monitoring, Prognostic monitoring, Targeted therapy

CLC Number:

LI Yilin, CHEN Yang, LI Yanyan, FENG Xujiao, ZHANG Cheng, LI Jian, SHEN Lin. Clinical application of circulating tumor cells in gastric cancer: advances and prospects[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 332-340.

References 59

[1]	SUVILESH K N, MANJUNATH Y, PANTEL K, et al. Preclinical models to study patient-derived circulating tumor cells and metastasis[J]. Trends Cancer, 2023, 9(4):355-371. doi: 10.1016/j.trecan.2023.01.004 pmid: 36759267
[2]	RING A, NGUYEN-STRÄULI B D, WICKI A, et al. Bio-logy, vulnerabilities and clinical applications of circula-ting tumour cells[J]. Nat Rev Cancer, 2023, 23(2):95-111. doi: 10.1038/s41568-022-00536-4
[3]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33. doi: 10.3322/caac.v72.1 URL
[4]	JOSHI S S, BADGWELL B D. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3):264-279. doi: 10.3322/caac.v71.3 URL
[5]	MA S, ZHOU M, XU Y, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer[J]. Mol Cancer, 2023, 22(1):7. doi: 10.1186/s12943-023-01715-z pmid: 36627698
[6]	LAWRENCE R, WATTERS M, DAVIES C R, et al. Circulating tumour cells for early detection of clinically relevant cancer[J]. Nat Rev Clin Oncol, 2023, 20(7):487-500. doi: 10.1038/s41571-023-00781-y pmid: 37268719
[7]	LONE S N, NISAR S, MASOODI T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments[J]. Mol Cancer, 2022, 21(1):79. doi: 10.1186/s12943-022-01543-7 pmid: 35303879
[8]	VISAL T H, DEN HOLLANDER P, CRISTOFANILLI M, et al. Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'[J]. Br J Cancer, 2022, 127(2):173-184. doi: 10.1038/s41416-022-01768-9
[9]	HOU J, GUO C, LYU G. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer[J]. Colorectal Dis, 2020, 22(5):581-587. doi: 10.1111/codi.14927 pmid: 31868956
[10]	CARNEIRO A, PIAIRO P, TEIXEIRA A, et al. Discriminating Epithelial to Mesenchymal Transition Phenotypes in Circulating Tumor Cells Isolated from Advanced Gastrointestinal Cancer Patients[J]. Cells, 2022, 11(3):376. doi: 10.3390/cells11030376 URL
[11]	MATSUSHITA D, UENOSONO Y, ARIGAMI T, et al. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer[J]. Cancer Chemother Pharmacol, 2021, 87(6):789-797. doi: 10.1007/s00280-021-04251-z
[12]	LI Y, ZHANG X, LIU D, et al. Evolutionary expression of her2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance[J]. Clin Cancer Res, 2018, 24(21):5261-5271. doi: 10.1158/1078-0432.CCR-18-1205 pmid: 30012565
[13]	JORDAN N V, BARDIA A, WITTNER B S, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells[J]. Nature, 2016, 537(7618):102-106. doi: 10.1038/nature19328
[14]	HAN S Y, PARK S H, KO H S, et al. Vimentin-positive circulating tumor cells as diagnostic and Prognostic biomarkers in patients with biliary tract cancer[J]. J Clin Med, 2021, 10(19):4435. doi: 10.3390/jcm10194435 URL
[15]	WEI T, ZHANG X, ZHANG Q, et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer[J]. Cancer Lett, 2019, 452:237-243. doi: S0304-3835(19)30165-X pmid: 30905814
[16]	CHEN Y, YUAN J, LI Y, et al. Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer[J]. Hum Cell, 2021, 34(5):1446-1454. doi: 10.1007/s13577-021-00568-2 pmid: 34152566
[17]	CHEN Y, LI Y, QI C, et al. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients[J]. Cancer Lett, 2021, 517:78-87. doi: 10.1016/j.canlet.2021.06.002 pmid: 34126192
[18]	WANG L, LI Y, XU J, et al. Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse[J]. Cancer Lett, 2018, 412:99-107. doi: 10.1016/j.canlet.2017.10.004 URL
[19]	KROL I, SCHWAB F D, CARBONE R, et al. Detection of clustered circulating tumour cells in early breast cancer[J]. Br J Cancer, 2021, 125(1):23-27. doi: 10.1038/s41416-021-01327-8
[20]	VISMARA M, REDUZZI C, SILVESTRI M, et al. Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Periphe-ral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma[J]. Clin Chem, 2022, 68(5):691-701. doi: 10.1093/clinchem/hvac019 URL
[21]	GLEGHORN J P, PRATT E D, DENNING D, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced diffe-rential immunocapture (GEDI) and a prostate-specific antibody[J]. Lab Chip, 2010, 10(1):27-29. doi: 10.1039/B917959C URL
[22]	SAUCEDO-ZENI N, MEWES S, NIESTROJ R, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire[J]. Int J Oncol, 2012, 41(4):1241-1250.
[23]	VASSEUR A, KIAVUE N, BIDARD F C, et al. Clinical utility of circulating tumor cells: an update[J]. Mol Oncol, 2021, 15(6):1647-1666. doi: 10.1002/1878-0261.12869 pmid: 33289351
[24]	LI Y, GONG J, ZHANG Q, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer[J]. Br J Cancer, 2016, 114(2):138-145. doi: 10.1038/bjc.2015.417
[25]	YU E, ALLAN A L, SANATANI M, et al. Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial[J]. BMC Cancer, 2022, 22(1):746. doi: 10.1186/s12885-022-09846-0 pmid: 35804307
[26]	LI Y, WU G, YANG W, et al. Prognostic value of circula-ting tumor cells detected with the CellSearch system in esophageal cancer patients: a systematic review and meta-analysis[J]. BMC Cancer, 2020, 20(1):581. doi: 10.1186/s12885-020-07059-x
[27]	KANG H M, KIM G H, JEON H K, et al. Circulating tumor cells detected by lab-on-a-disc: Role in early diagnosis of gastric cancer[J]. PLoS One, 2017, 12(6):e0180251. doi: 10.1371/journal.pone.0180251 URL
[28]	ISEBIA K T, MOSTERT B, BELDERBOS B P S, et al. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients[J]. Eur J Cancer, 2022, 177:33-44. doi: 10.1016/j.ejca.2022.09.032 pmid: 36323051
[29]	JACOT W, COTTU P, BERGER F, et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial[J]. Breast Cancer Res, 2019, 21(1):121. doi: 10.1186/s13058-019-1215-z
[30]	ARMSTRONG A J, HALABI S, LUO J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study[J]. J Clin Oncol, 2019, 37(13):1120-1129. doi: 10.1200/JCO.18.01731 pmid: 30865549
[31]	PARKER C, CASTRO E, FIZAZI K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(9):1119-1134. doi: S0923-7534(20)39898-7 pmid: 32593798
[32]	NEGISHI R, YAMAKAWA H, KOBAYASHI T, et al. Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer[J]. Commun Biol, 2022, 5(1):20. doi: 10.1038/s42003-021-02937-x pmid: 35017627
[33]	BRACKEN C P, GOODALL G J. The many regulators of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2022, 23(2):89-90. doi: 10.1038/s41580-021-00442-x
[34]	SCHUSTER E, TAFTAF R, REDUZZI C, et al. Better together: circulating tumor cell clustering in metastatic cancer[J]. Trends Cancer, 2021, 7(11):1020-1032. doi: 10.1016/j.trecan.2021.07.001 pmid: 34481763
[35]	SZCZERBA B M, CASTRO-GINER F, VETTER M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature, 2019, 566(7745):553-557. doi: 10.1038/s41586-019-0915-y
[36]	DUDA D G, DUYVERMAN A M, KOHNO M, et al. Malignant cells facilitate lung metastasis by bringing their own soil[J]. Proc Natl Acad Sci U S A, 2010, 107(50):21677-21682. doi: 10.1073/pnas.1016234107 URL
[37]	SPROUSE M L, WELTE T, BORAL D, et al. PMN-MDSCs Enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling[J]. Int J Mol Sci, 2019, 20(8):1916. doi: 10.3390/ijms20081916 URL
[38]	CASTRO-GINER F, ACETO N. Tracking cancer progression: from circulating tumor cells to metastasis[J]. Genome Med, 2020, 12(1) 31. doi: 10.1186/s13073-020-00728-3
[39]	NI X, ZHUO M, SU Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients[J]. Proc Natl Acad Sci U S A, 2013, 110(52):21083-21088. doi: 10.1073/pnas.1320659110 URL
[40]	GASCH C, OLDOPP T, MAUERMANN O, et al. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer[J]. Mol Oncol, 2016, 10(8):1330-1343. doi: 10.1016/j.molonc.2016.07.005 pmid: 27491860
[41]	FAUGEROUX V, LEFEBVRE C, PAILLER E, et al. An accessible and unique insight into metastasis mutational content through whole-exome sequencing of circulating tumor cells in metastatic prostate cancer[J]. Eur Urol Oncol, 2020, 3(4):498-508. doi: S2588-9311(18)30213-X pmid: 31412010
[42]	DONATO C, KUNZ L, CASTRO-GINER F, et al. Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells[J]. Cell Rep, 2020, 32(10):108105. doi: 10.1016/j.celrep.2020.108105 URL
[43]	ZHANG H, WONG C C, WEI H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs[J]. Oncogene, 2012, 31(10):1757-1770. doi: 10.1038/onc.2011.365
[44]	HARNEY A S, ARWERT E N, ENTENBERG D, et al. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA[J]. Cancer Discov, 2015, 5(9):932-943. doi: 10.1158/2159-8290.CD-15-0012 pmid: 26269515
[45]	MERINO D, WEBER T S, SERRANO A, et al. Barco-ding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer[J]. Nat Commun, 2019, 10(1):766. doi: 10.1038/s41467-019-08595-2
[46]	LEE H J, DIAZ M F, PRICE K M, et al. Fluid shear stress activates YAP1 to promote cancer cell motility[J]. Nat Commun, 2017, 8:14122. doi: 10.1038/ncomms14122 pmid: 28098159
[47]	HEADLEY M B, BINS A, NIP A, et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung[J]. Nature, 2016, 531(7595):513-517. doi: 10.1038/nature16985
[48]	HAEMMERLE M, TAYLOR M L, GUTSCHNER T, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling[J]. Nat Commun, 2017, 8(1):310. doi: 10.1038/s41467-017-00411-z pmid: 28827520
[49]	OSMANI N, FOLLAIN G, GARCÍA LEÓN M J, et al. Metastatic Tumor Cells Exploit Their Adhesion Repertoire to Counteract Shear Forces during Intravascular Arrest[J]. Cell Rep, 2019, 28(10):2491-2500. doi: S2211-1247(19)31018-6 pmid: 31484062
[50]	CHEN M B, HAJAL C, BENJAMIN D C, et al. Inflamed neutrophils sequestered at entrapped tumor cells via chemotactic confinement promote tumor cell extravasation[J]. Proc Natl Acad Sci U S A, 2018, 115(27):7022-7027. doi: 10.1073/pnas.1715932115 URL
[51]	季加孚, 李沈, 陕飞, 等. 胃癌规范化诊疗与质量控制[J]. 中华消化外科杂志, 2023, 22(3):322-325.
	JI JF, LI S, SHAN F,etal. Standardized diagnosis and treatment and quality control of gastric cancer[J]. Chin J Dig Surg, 2023, 22(3):322-325.
[52]	赫捷, 陈万青, 李兆申, 等. 中国胃癌筛查与早诊早治指南(2022,北京)[J]. 中华消化外科杂志,2022, 21(7):827-851.
	HAO J, CHEN WQ, LI ZS, et al. China guideline for the screening, early detection and early treatment of gastric cancer (2022, Beijing)[J]. Chin J Dig Surg, 2022, 21(7):827-851.
[53]	徐泽宽, 王森, 汪未知. 胃癌的综合治疗[J]. 中华消化外科杂志, 2022, 21(3):335-341.
	XU ZK, WANG S, WANG WZ. Comprehensive treatment of gastric cancer[J]. 2022, 21(3):335-341.
[54]	TSILIMIGRAS D I, BRODT P, CLAVIEN P A, et al. Liver metastases[J]. Nat Rev Dis Primers, 2021, 7(1):27. doi: 10.1038/s41572-021-00261-6 pmid: 33859205
[55]	SUN Y F, WU L, LIU S P, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1):4091. doi: 10.1038/s41467-021-24386-0
[56]	GUO X, LIN F, YI C, et al. Deep transfer learning enables lesion tracing of circulating tumor cells[J]. Nat Commun, 2022, 13(1):7687. doi: 10.1038/s41467-022-35296-0 pmid: 36509761
[57]	PEREIRA-VEIGA T, SCHNEEGANS S, PANTEL K, et al. Circulating tumor cell-blood cell crosstalk: biology and clinical relevance[J]. Cell Rep, 2022, 40(9):111298. doi: 10.1016/j.celrep.2022.111298 URL
[58]	RODRIGUEZ-MARTINEZ A, SIMON-SAEZ I, PERALES S, et al. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior[J]. Theranostics, 2022, 12(5):2150-2161. doi: 10.7150/thno.64252 URL
[59]	FU A, YAO B, DONG T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer[J]. Cell, 2022, 185(8):1356-1372. doi: 10.1016/j.cell.2022.02.027 pmid: 35395179